GUFICBIO2024-07-012024-09-30 GUFICBIO2024-07-012024-09-30 GUFICBIO2024-07-012024-09-30in-bse-fin:OneOperatingExpenses01Member GUFICBIO2024-07-012024-09-30in-bse-fin:FourOperatingExpenses01Member GUFICBIO2024-09-30 iso4217:INRxbrli:purexbrli:sharesiso4217:INRxbrli:shares 509079 GUFICBIO NOTLISTED Gufic Biosciences Limited Equity 2024-04-01 2025-03-31 2024-11-14 2024-11-08 INR Lakhs Half yearly 17:45:00 19:15:00 2024-11-14 2024-11-14 true Cash Flow Indirect Not applicable Single segment The Company's business activity falls within a single operating segment i.e. Pharmaceuticals 2024-07-01 2024-09-30 Unaudited Consolidated 2041799000.00 1138000.00 2042937000.00 749349000.00 165699000.00 46242000.00 284721000.00 51786000.00 42979000.00 409628000.00 1750404000.00 292533000.00 0.00 292533000.00 75000000.00 -147000.00 74853000.00 0.00 217680000.00 0.00 0.00 0.00 0.00 217680000.00 0.00 217680000.00 0.00 -6000.00 0.00 0.00 100278000.00 1 2.17 2.17 0.00 0.00 2.17 2.17 0.00 0.00 0.00 1. The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards), Rules, 2015 (Ind AS) as amended, prescribed under section 133 of Companies Act, 2013, read with rules issued thereunder. 2. The above results for the quarter ended September 30, 2024 have been reviewed by the Audit Committee and approved by the Board of Directors at their meetings held on November 14, 2024.The Statutory Auditors have carried out limited review of the results for quarter and half-year ended September 30, 2024. 3. The Company's business activity falls within a single operating segment i.e. Pharmaceuticals. 4. The Company has incorporated Gufic UK Limited ( GUL ) in United Kingdom on March 15, 2022, Gufic Ireland Limited ( GIL ) in Ireland on March 02, 2023, Veira Life FZE ( VLF ) in Dubai, UAE on March 25, 2024 and Gufic Prime Private Limited (“GPPL”) in India on November 18, 2023, with the intention of making GUL, GIL and VLF its Wholly Owned Subsidiaries and GPPL as its Subsidiary Company. As of September 30, 2024, neither investment have been made in GIL and VLF nor they have begun their business operations. Consequently, there was no need to consolidate the accounts of GIL and VLF with the Company. However, the Company has invested in GUL on September 13, 2023 and in GPPL on April 25, 2024 by subscribing to its shares. Consequently, the consolidated financial results for the quarter and half year ended September 30, 2024, have been prepared by the Company considering the financials of GUL and GPPL. 5. The Company obtained all requisite licenses, including the FDA license, factory license, Madhya Pradesh Pollution Control Board (MPPCB) consent, as well as approvals for electricity and water connections for its manufacturing facility in Indore by October 2023. This facility became operational and functional and began fulfilling manufacturing requirements for products that were initially intended to be produced at the Navsari facility, due to capacity constraints at the latter. However, in light of evolving US FDA requirements and the need for additional documentation and validations for the US market, the Board of Directors made a strategic decision to complete all necessary US FDA-related formalities before proceeding with commercialization. All required studies and validations have been completed, and production has commenced. 6. The equity shares and basic/diluted earnings per share has been presented in accordance with Ind AS - 33-Earning per share. 7. Previous year/quarters figures have been regrouped/reclassified, wherever necessary. Single segment 2024-04-01 2024-09-30 Unaudited Consolidated 4069919000.00 13684000.00 4083603000.00 1477017000.00 290159000.00 141503000.00 575184000.00 98027000.00 86030000.00 842103000.00 3510023000.00 573580000.00 0.00 573580000.00 145000000.00 2339000.00 147339000.00 0.00 426241000.00 0.00 0.00 0.00 0.00 426241000.00 0.00 426241000.00 0.00 -7000.00 0.00 0.00 100278000.00 1 4.25 4.25 0.00 0.00 4.25 4.25 0.00 0.00 0.00 Other Expenses 409628000.00 Other Expenses 842103000.00 12000.00 1429313000.00 3631914000.00 0.00 0.00 63495000.00 0.00 0.00 0.00 17843000.00 0.00 2553000.00 99133000.00 119529000.00 2000.00 18574000.00 5262827000.00 1868366000.00 0.00 3108394000.00 57370000.00 136585000.00 3517000.00 0.00 3305866000.00 0.00 609645000.00 5783877000.00 0.00 0.00 11046704000.00 100278000.00 5641511000.00 5741789000.00 5741801000.00 1427975000.00 0.00 146503000.00 1574478000.00 165001000.00 22974000.00 0.00 0.00 1762453000.00 1407981000.00 1685984000.00 123714000.00 3217679000.00 206595000.00 48832000.00 69344000.00 0.00 3542450000.00 0.00 0.00 5304903000.00 11046704000.00 0.00 136455000.00 134582000.00 0.00 0.00 0.00 0.00 0.00 0.00 -43760000.00 0.00 0.00 0.00 86030000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 313307000.00 886887000.00 0.00 -98027000.00 -6985000.00 89009000.00 5157000.00 894077000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 47658000.00 408583000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 3802000.00 0.00 -13113000.00 0.00 -370236000.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 334806000.00 0.00 35397000.00 10028000.00 97609000.00 0.00 0.00 -477840000.00 46001000.00 0.00 46001000.00 11369000.00 57370000.00